| Outcome Measures: |
Primary: Change in flow mediated dilation, Percent, From Visit 3B (week 0) to visit 30B (week 26) | Secondary: Change in pulse wave velocity, m/s, From Visit 3B (week 0) to visit 30B (week 26)|Change in leg blood flow, ml/100 ml/min, From Visit 3B (week 0) to visit 30B (week 26)|Change in retinal arteriolar dilation, Percent, From Visit 3A (week 0) to visit 30A (week|Relative change in liver fat percentage measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), Ratio, From Visit 2 (week 0) to visit 29 (week 26)|Change in left ventricular ejection fraction, Percent, From Visit 2 (week 0) to visit 29 (week 26)|Change in glycosylated haemoglobin (HbA1c ), Percent, From Visit 3B (week 0) to visit 30B (week 26)|Change in body weight, kg, From Visit 3B (week 0) to visit 30B (week 26)|Change in body fat mass as measured by BOD POD (a method for determining the lean body mass), Percent, From Visit 3B (week 0) to visit 30B (week 26)|Relative change in rate of glucose disposal at short Insulin Tolerance Test, Ratio, From Visit 3B (week 0) to visit 30B (week 26)|Number of adverse events, Number of events, From Visit 3B (week 0) to visit 30B (week 26)|Number of severe hypoglycaemic episodes (level 3), Number of episodes, From Visit 3B (week 0) to visit 30B (week 26)|Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3), Number of episodes, From Visit 3B (week 0) to visit 30B (week 26)|Number of clinically significant hypoglycaemic episodes s (level 2) ((below 3.0 mmol/L (54 mg/dL), confirmed by BG meter), Number of episodes, From Visit 3B (week 0) to visit 30B (week 26)
|
